Oral Ketamine Trial on Suicidality
An open-label clinical trial of oral ketamine, an NMDA (N-methyl-D-aspartate) receptor antagonist, with weekly dosing over six weeks, in 25-50 patients who are experiencing chronic suicidal ideation.
Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast
50 participants
Aug 2, 2018
Interventional
Conditions
Summary
This study is an open-label clinical trial aiming to explore the effectiveness, feasibility and tolerability of oral ketamine on suicidality. The pathology and neurobiology of suicidality will be examined via MRI and EEG as neurological measures. The primary outcome of change in suicidality will be assessed using the Beck Scale for Suicide Ideation.
Eligibility
Inclusion Criteria3
- Patients with chronic suicidal thoughts as the primary presenting complaint, determined by a score of greater than or equal to 6 for the Scale for Suicide Ideation (BSS)
- Persons (male/female/other) aged over 18 years
- Participant to receive physical examination from Principal Investigator within 14 days prior to commencement of ketamine treatment to eliminate possibility of conditions outlined in
Exclusion Criteria11
- Participants must be able to understand the PIF and provide written informed consent on the Participant Consent Form (PCF)
- Persons under 18 years of age
- Psychosis
- Mania/hypomania
- Acute suicidality requiring urgent psychiatric intervention
- Uncontrolled/severe symptomatic cardiovascular disease states including: recent myocardial infarction (within prior 6 months); history of stroke; and hypertension (resting blood pressure >150/100)
- History of intracranial mass, intracranial haemorrhage/stroke, cerebral trauma/traumatic brain injury or increased intracranial pressure (as assessed by referring general practitioner)
- Liver function test (LFT) results that exceed the upper level of normal range by 3 times
- Previous reaction to ketamine (as reported by referring general practitioner and participant)
- Pregnant women
- Breastfeeding women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be administered a weekly sub anaesthetic dose of ketamine (oral liquid formulation) for six consecutive weeks beginning at 0.5mg/kg and titrated to 3.0mg/kg. Dosing will increase by 0.1 - 0.5mg/kg each week for participants who tolerate the previous dose, with dosing determined by a Psychiatrist. Dosing will be administered at the trial site under direct supervision of the Psychiatrist, and participants will be monitored for one hour by a Mental Health Nurse Practitioner or Mental Health Nurse Research Officer prior to leaving the site.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12618001412224